VACCINE COMBINATION

Moderna jumps as vaccine shows benefit in head and neck cancer in early study

Moderna shares rose 8% to a three-month high on Tuesday after the company's individualized cancer vaccine developed with Merck showed positive response in an early-stage trial in patients with a type of head and neck cancer.